Veracyte, Inc. Stock price

Equities

VCYT

US92337F1075

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:51:20 2024-03-01 pm EST 5-day change 1st Jan Change
24.44 USD +3.80% Intraday chart for Veracyte, Inc. +10.30% -11.07%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2023 361M Sales 2024 * 398M Capitalization 1.72B
Net income 2023 -74M Net income 2024 * -17M EV / Sales 2023 5.57 x
Net cash position 2023 * 202M Net cash position 2024 * 220M EV / Sales 2024 * 3.77 x
P/E ratio 2023
-27 x
P/E ratio 2024 *
-98.1 x
Employees 787
Yield 2023 *
-
Yield 2024 *
-
Free-Float 95.65%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.93%
1 week-3.25%
1 month-5.88%
3 months-8.01%
6 months-10.80%
Current year-14.39%
More quotes
1 week
21.86
Extreme 21.86
24.36
1 month
21.86
Extreme 21.86
26.59
Current year
21.86
Extreme 21.86
29.16
1 year
19.52
Extreme 19.52
30.52
3 years
14.85
Extreme 14.85
64.29
5 years
13.90
Extreme 13.9
86.03
10 years
4.21
Extreme 4.21
86.03
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 21-05-31
Director of Finance/CFO 46 21-07-18
Chief Tech/Sci/R&D Officer - 22-06-30
Members of the board TitleAgeSince
Director/Board Member 67 08-01-31
Chairman 69 15-01-11
Director/Board Member 74 12-11-30
More insiders
Date Price Change Volume
24-03-01 24.46 +3.89% 279 829
24-02-29 23.55 -0.93% 719,903
24-02-28 23.77 +0.64% 701,966
24-02-27 23.62 +0.25% 902,038
24-02-26 23.56 +6.22% 1,179,726

Delayed Quote Nasdaq, February 29, 2024 at 04:00 pm EST

More quotes
Veracyte, Inc. is a global diagnostics company. The Company is engaged in the development and commercialization of diagnostic products and biopharmaceutical services. It offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. It also offers an Immunogram, which provides an understanding of the tumor immune microenvironment by integrating data from a variety of genomic, transcriptomic, and proteomic platforms. Its tests in the United States are serviced through its own CLIA-certified laboratories in South San Francisco and San Diego, California and Austin, Texas. It also offers customized biomarker testing and analytical services.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
23.55 USD
Average target price
31.67 USD
Spread / Average Target
+34.47%
Consensus
  1. Stock
  2. Equities
  3. Stock Veracyte, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW